We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 11. | 장 마감 후 (AMC) | $-0.42 | — | — | $0 | — | 예정 |
Consensus PT $7.4 · 5 analysts
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 530,812 | $1.25B | 0.00% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 143,221 | $302.2M | 0.00% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Stored first · Google News · Yahoo Finance (English)
Is Acumen Pharmaceuticals (ABOS) stock outpacing its medical peers this year? - MSN
Is Acumen Pharmaceuticals (ABOS) stock outpacing its medical peers this year? MSN
ABOS Technical Analysis | Trend, Signals & Chart Patterns | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) - ChartMill
ABOS Technical Analysis | Trend, Signals & Chart Patterns | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) ChartMill
ABOS - Finviz
ABOS Finviz
Acumen’s Late-2026 Sabirnetug Readout Is A Viable Bet (NASDAQ:ABOS) - Seeking Alpha
Acumen’s Late-2026 Sabirnetug Readout Is A Viable Bet (NASDAQ:ABOS) Seeking Alpha
Bank of America Securities Remains a Buy on Acumen Pharmaceuticals (ABOS) - The Globe and Mail
Bank of America Securities Remains a Buy on Acumen Pharmaceuticals (ABOS) The Globe and Mail
Earnings call transcript: Acumen Pharmaceuticals beats Q1 2026 EPS forecast - Investing.com
Earnings call transcript: Acumen Pharmaceuticals beats Q1 2026 EPS forecast Investing.com